Pasar al contenido principal

DECIPHERING THE ROLE OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM METABOTROPIC GLUTAMATE RECEPTORS IN NEUROPHATIC PAIN WITH PHOTOACTIVABLE LIGANDS

PCIN-2013-018-C03-02

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos Programación Conjunta Internacional
Año convocatoria 2013
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator

  • Nonell, Santi
  • Bresolí-Obach, Roger
  • Font Inglès, Joan
  • López-Cano, Marc
  • Notartomaso, Serena
  • Scarselli, Pamela
  • Di Pietro, Paola
  • Battaglia, Giuseppe
  • Malhaire, Fanny
  • Rovira, Xavier
  • Catena, Juanlo
  • Giraldo, Jesús
  • Pin, Jean-Philippe
  • Fernández-Dueñas, Víctor
  • Goudet, Cyril
  • Nicoletti, Ferdinando
  • Llebaria, Amadeu
  • Ciruela, Francisco
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu5) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug’s release, which effectively controls mGlu5 receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu5 receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator

  • Nonell, Santi
  • Bresolí-Obach, Roger
  • Font Inglès, Joan
  • López-Cano, Marc
  • Notartomaso, Serena
  • Scarselli, Pamela
  • Di Pietro, Paola
  • Battaglia, Giuseppe
  • Malhaire, Fanny
  • Rovira, Xavier
  • Catena, Juanlo
  • Giraldo, Jesús
  • Pin, Jean-Philippe
  • Fernández-Dueñas, Víctor
  • Goudet, Cyril
  • Nicoletti, Ferdinando
  • Llebaria, Amadeu
  • Ciruela, Francisco
Light-operated drugs constitute a major target in drug discovery, since they may provide spatiotemporal resolution for the treatment of complex diseases (i.e. chronic pain). JF-NP-26 is an inactive photocaged derivative of the metabotropic glutamate type 5 (mGlu5) receptor negative allosteric modulator raseglurant. Violet light illumination of JF-NP-26 induces a photochemical reaction prompting the active-drug’s release, which effectively controls mGlu5 receptor activity both in ectopic expressing systems and in striatal primary neurons. Systemic administration in mice followed by local light-emitting diode (LED)-based illumination, either of the thalamus or the peripheral tissues, induced JF-NP-26-mediated light-dependent analgesia both in neuropathic and in acute/tonic inflammatory pain models. These data offer the first example of optical control of analgesia in vivo using a photocaged mGlu5 receptor negative allosteric modulator. This approach shows potential for precisely targeting, in time and space, endogenous receptors, which may allow a better management of difficult-to-treat disorders.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Shining Light On An mGlu5 Photoswitchable NAM, A Theoretical Perspective

  • Dalton, James A. R.|||0000-0002-5279-4581
  • Lans, Isaias|||0000-0002-9298-0346
  • Rovira Algans, Xavier
  • Malhaire, Fanny
  • Gómez-Santacana, Xavier|||0000-0001-8830-0494
  • Pittolo, Silvia|||0000-0002-5673-1692
  • Gorostiza, Pau|||0000-0002-7268-5577
  • Llebaria, Amadeu|||0000-0002-8200-4827
  • Goudet, Cyril|||0000-0002-8255-3535
  • Pin, Jean-Philippe|||0000-0002-1423-345X
  • Giraldo, Jesús|||0000-0001-7082-4695
Metabotropic glutamate receptors (mGluRs) are important drug targets because of their involvement in several neurological diseases. Among mGluRs, mGlu5 is a particularly high-profile target because its positive or negative allosteric modulation can potentially treat schizophrenia or anxiety and chronic pain, respectively. Here, we computationally and experimentally probe the functional binding of a novel photoswitchable mGlu5 NAM, termed alloswitch-1, which loses its NAM functionality under violet light. We show alloswitch-1 binds deep in the allosteric pocket in a similar fashion to mavoglurant, the co-crystallized NAM in the mGlu5 transmembrane domain crystal structure. Alloswitch-1, like NAM 2-Methyl-6-(phenylethynyl)pyridine (MPEP), is significantly affected by P655M mutation deep in the allosteric pocket, eradicating its functionality. In MD simulations, we show alloswitch-1 and MPEP stabilize the co-crystallized water molecule located at the bottom of the allosteric site that is seemingly characteristic of the inactive receptor state. Furthermore, both NAMs form H-bonds with S809 on helix 7, which may constitute an important stabilizing interaction for NAM-induced mGlu5 inactivation. Alloswitch-1, through isomerization of its amide group from trans to cis is able to form an additional interaction with N747 on helix 5. This may be an important interaction for amide-containing mGlu5 NAMs, helping to stabilize their binding in a potentially unusual cis-amide state. Simulated conformational switching of alloswitch-1 in silico suggests photoisomerization of its azo group from trans to cis may be possible within the allosteric pocket. However, photoexcited alloswitch-1 binds in an unstable fashion, breaking H-bonds with the protein and destabilizing the co-crystallized water molecule. This suggests photoswitching may have destabilizing effects on mGlu5 binding and functionality.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Angiotensin II type 1/adenosine A receptor oligomers, a novel target for tardive dyskinesia

  • Oliveira, Paulo A. de|||0000-0002-0852-4920
  • Dalton, James A. R.|||0000-0002-5279-4581
  • López Cano, Marc|||0000-0001-8885-3726
  • Ricarte, Adrià
  • Morató, Xavier|||0000-0002-3012-2864
  • Matheus, Filipe C.
  • Cunha, Andréia S.
  • Müller, Christa E.
  • Takahashi, Reinaldo N.
  • Fernández-Dueñas, Víctor|||0000-0001-7834-2965
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Prediger, Rui D.
  • Ciruela, Francisco|||0000-0003-0832-3739
Tardive dyskinesia (TD) is a serious motor side effect that may appear after long-term treatment with neuroleptics and mostly mediated by dopamine D receptors (DRs). Striatal DR functioning may be finely regulated by either adenosine A receptor (AR) or angiotensin receptor type 1 (ATR) through putative receptor heteromers. Here, we examined whether AR and ATR may oligomerize in the striatum to synergistically modulate dopaminergic transmission. First, by using bioluminescence resonance energy transfer, we demonstrated a physical ATR-AR interaction in cultured cells. Interestingly, by protein-protein docking and molecular dynamics simulations, we described that a stable heterotetrameric interaction may exist between ATR and AR bound to antagonists (i.e. losartan and istradefylline, respectively). Accordingly, we subsequently ascertained the existence of ATR/AR heteromers in the striatum by proximity ligation in situ assay. Finally, we took advantage of a TD animal model, namely the reserpine-induced vacuous chewing movement (VCM), to evaluate a novel multimodal pharmacological TD treatment approach based on targeting the ATR/AR complex. Thus, reserpinized mice were co-treated with sub-effective losartan and istradefylline doses, which prompted a synergistic reduction in VCM. Overall, our results demonstrated the existence of striatal ATR/AR oligomers with potential usefulness for the therapeutic management of TD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Pharmacological evidence for a metabotropic glutamate receptor heterodimer in neuronal cells

  • Moreno Delgado, David|||0000-0003-0070-2566
  • Møller, Thor C.|||0000-0002-2256-577X
  • Ster, Jeanne
  • Giraldo, Jesús|||0000-0001-7082-4695
  • Maurel, Damien
  • Rovira, Xavier|||0000-0002-9764-9927
  • Scholler, Pauline
  • Zwier, Jurriaan M.|||0000-0001-9017-5856
  • Perroy, Julie
  • Durroux, Thierry
  • Trinquet, Eric
  • Prezeau, Laurent
  • Rondard, Philippe|||0000-0003-1134-2738
  • Pin, Jean-Philippe|||0000-0002-1423-345X
Metabotropic glutamate receptors (mGluRs) are mandatory dimers playing important roles in regulating CNS function. Although assumed to form exclusive homodimers, 16 possible heterodimeric mGluRs have been proposed but their existence in native cells remains elusive. Here, we set up two assays to specifically identify the pharmacological properties of rat mGlu heterodimers composed of mGlu2 and 4 subunits. We used either a heterodimer-specific conformational LRET-based biosensor or a system that guarantees the cell surface targeting of the heterodimer only. We identified mGlu2-4 specific pharmacological fingerprints that were also observed in a neuronal cell line and in lateral perforant path terminals naturally expressing mGlu2 and mGlu4. These results bring strong evidence for the existence of mGlu2-4 heterodimers in native cells. In addition to reporting a general approach to characterize heterodimeric mGluRs, our study opens new avenues to understanding the pathophysiological roles of mGlu heterodimers.